Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Castelli, Chiara ^a   Tazzari, Marcella ^a   Negri, Tiziana ^b   Vergani, Barbara ^c   Rivoltini, Licia ^a   Stacchiotti, Silvia ^a   Pilotti, Silvana ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b U of Exp Molecular Pathology   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Anti angiogenic therapy; Immune infiltrating cells; Inflammation; Myeloid cells; Soft tissue sarcoma

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BISPHOSPHONIC ACID DERIVATIVE; CD163 ANTIGEN; CEDIRANIB; CHEMOKINE RECEPTOR CXCR7; FOLATE RECEPTOR 1; MONOCYTE CHEMOTACTIC PROTEIN 1; RETINOIC ACID; TRABECTEDIN; TRITERPENOID; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ALVEOLAR SOFT PART SARCOMA; ANTIANGIOGENIC THERAPY; BONE MARROW CELL; BONE METASTASIS; DOWN REGULATION; GENE EXPRESSION; HUMAN; MACROPHAGE; NOTE; TUMOR ASSOCIATED LEUKOCYTE;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; INFLAMMATION; MACROPHAGES; MICE; MYELOID CELLS; NEOPLASM METASTASIS; SARCOMA, ALVEOLAR SOFT PART; TUMOR MICROENVIRONMENT;

EID: 84884962626     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-237     Document Type: Note

References (18)

1. Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol 2013, 31:2296-2302. 10.1200/JCO.2012.47.4288, 23630200.
2. Moss A. The angiopoietin: Tie 2 interaction: A potential target for future therapies in human vascular disease. Cytokine Growth Factor Rev 2013, S1359-6101(13):00057-00059.
3. Haffner MC, Laimer J, Chaux A, Schafer G, Obrist P, Brunner A, Kronberger IE, Laimer K, Gurel B, Koller JB, Seifarth C, Zelger B, Klocker H, Rasse M, Doppler W, Bander NH. High expression of prostate-specific membrane antigen in the tumor-associated neo vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol 2012, 25:1079-1085. 10.1038/modpathol.2012.66, 22460809.
4. Monnier J, Boissan M, L'Helgoualc'h A, Lacombe ML, Turlin B, Zucman-Rossi J, Theret N, Piquet-Pellorce C, Samson M. CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur J Cancer 2012, 48:138-148.
5. Yan X, Cai S, Xiong X, Sun W, Dai X, Chen S, Ye Q, Song Z, Jiang Q, Xu Z. Chemokine receptor CXCR7 mediates human endothelial progenitor cells survival, angiogenesis, but not proliferation. J Cell Biochem 2012, 113:1437-1446. 10.1002/jcb.24015, 22173725.
6. Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, Rogler A, Stohr R, Hartmann A, Provenzano M, Otto VI, Detmar M. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 2013, 73:1097-1106. 10.1158/0008-5472.CAN-12-1855, 23243026.
7. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, De Palma M. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526. 10.1016/j.ccr.2011.02.005, 21481792.
8. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 2009, 15:1096-1104. 10.1158/1078-0432.CCR-08-2050, 19188185.
9. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, Gronchi A, Casali PG, Pilotti S. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol 2011, 22:1682-1690. 10.1093/annonc/mdq644, 21242589.
10. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001, 23:263-272. 10.1385/IR:23:2-3:263, 11444391.
11. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013, 31:2205-2218. 10.1200/JCO.2012.46.3653, 23669226.
12. Matzinger P. Friendly and dangerous signals: is the tissue in control?. Nat Immunol 2007, 8:11-13. 10.1038/ni0107-11, 17179963.
13. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012, 109:17561-17566. 10.1073/pnas.1215397109, 3491458, 23045683.
14. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010, 207:2439-2453. 10.1084/jem.20100587, 2964584, 20876310.
15. Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 2013, 62:909-918. 10.1007/s00262-013-1396-8, 23589106.
16. Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 2010, 15:16(6):1812-1823.
17. Allavena P, Germano G, Belgiovine C, D'Incalci M, Mantovani A. Trabectedin: A drug from the sea that strikes tumor-associated macrophages. Oncoimmunology 2013, 2:e24614. 10.4161/onci.24614, 3716756, 23894721.
18. Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med 2011, 9(177):5876-5879.